Journal article

Credentialing of vertebral stereotactic ablative body radiotherapy in a multi-centre trial

Nicholas Hardcastle, Tomas Kron, Olivia Cook, Joerg Lehmann, Paul LR Mitchell, Shankar Siva

Physica Medica | ELSEVIER SCI LTD | Published : 2020


PURPOSE/OBJECTIVE: Stereotactic ablative body radiotherapy (SABR) in multi-centre trials requires rigorous quality assurance to ensure safe and consistent treatment for all trial participants. We report results of vertebral SABR dosimetry credentialing for the ALTG/TROG NIVORAD trial. MATERIAL/METHODS: Centres with a previous SABR site visit performed axial film measurement of the benchmarking vertebral plan in a local phantom and submitted radiochromic film images for analysis. Remaining centres had on-site review of SABR processes and axial film measurement of the vertebral benchmarking plan. Films were analysed for dosimetric and positional accuracy: gamma analysis (>90% passing 2%/2mm/10..

View full abstract


Funding Acknowledgements

The Australasian Lung Cancer Trials Group, Trans Tasman Radiation Oncology Group NIVORAD Trial including quality assurance site visits was funded by Bristol-Myers Squibb Company. Shankar Siva is supported by a Peter MacCallum Cancer Centre Foundation Discovery Fellowship, National Health and Medical Research Council Fellowship.